Cancer Research Technology
Log in Register
Menu
Search
Monoclonal Antibodies

Anti-EBV Latent Membrane Protein 1 [LMPO24]

Invented by Prof Martin Rowe from University Of Birmingham
Invented at University Of Birmingham
  • Datasheet
  • Inventor Info
Print

Info

Image thumbnail for Anti-EBV Latent Membrane Protein 1 [LMPO24]
Add an image
Intracellular staining of LMP1 using LMPO24 antibody. NK and T cell lines were fixed and permeabilised with an EBiosciences kit (Cat 88-8824-00) then stained with LMPO24 monoclonal antibody, followed by detection with Alexa Fluor 488 conjugated anti-mouse IgG antibody and analysis by flow cytometry. The histograms show negative control fluorescence staining (black lines) and LMPO24 staining (red lines). MEC04, SNK1, SNK6 and SNT8 are EBV positive tumour cell lines derived from patients with nasal NK/T cell lymphomas. MEC04, SNK1 and SNK6 are NK cell lines, while SNT8 is a T cell line. MEC04 lacks LMP1 expression, SNK1 expresses weak to moderate levels of LMP1, whilst SNK6 and SNT8 express high levels of LMP1.
Add an image
Image thumbnail for Anti-EBV Latent Membrane Protein 1 [LMPO24]
Catalogue Number 152632
Applications FACS IHC
Antigen/Gene or Protein Targets Epstein-Barr Virus, Latent Membrane Protein 1 (EBV-LMP1)
Reactivity Virus
Relevance Monoclonal antibody which can be used to investigate EBV latency and EBV-associated malignant cells.

Background and Research Application
EBV is a human herpesvirus that establishes a life-long persistence in the host. The virus infects the vast majority of the world's adult population and is well known for its association with a broad spectrum of benign and malignant diseases. These include infectious mononucleosis, Burkitt's lymphoma, nasopharyngeal carcinoma, and is causally associated with lymphoid and epithelial malignancies, including post-transplant lymphoproliferative disorders, Hodgkin's disease, anaplastic nasopharyngeal carcinoma and gastric carcinomas.

This antibody is specific for latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV). LMP1 is a transforming protein that affects multiple cell signalling pathways and contributes to EBV-associated oncogenesis. This protein can be expressed in some states of EBV latency, and significant induction of full-length LMP1 is also observed frequently during virus reactivation into the lytic cycle. LMP1 is critical for EBV-infected cell activation, adhesion and survival, and is usually expressed in the malignant cells.
Host Mouse
Immunogen Purified plasma membranes from LMP1 expressing insect cells infected with a recombinant LMP1 baculovirus
Immunogen UniProt ID P03230
Positive Control EBV transformed lymphoblastoid cell lines
Subclass IgG1 kappa
Strain Balb/c
Notes Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
Anti-LMP1 has a strong and specific reactivity in immunohistochemical staining of paraffin-embedded tissues.
LMP024 helped show many LMP1-positive large lymphoid blasts.

Niedobitek et al., 1995: "The LMPO24 clone demonstrates strong and specific reactivity in immunohistochemical staining of paraffin-embedded tissues".

Concentration
1mg/ml as standard
Research Area Adhesion, Cancer, Cell Signaling & Signal Transduction, Immunology, Virology

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Niedobitek et al. 1995. Blood. 86(2):659-65. PMID: 7605996.

IHC

View  

Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.

Europe PMC ID: 7605996

View  

Add a reference

References: 2 entries

Niedobitek et al. 1995. Blood. 86(2):659-65. PMID: 7605996.

IHC

View  

Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.

View  

Add a reference

Inventor Information